MAPT and supranuclear palsy, progressive, 1: In contrast, reducing the affinity of oligomeric tau to its receptor in the PSP case from 0.3 nM to 1600 nM improves the effect of 4500 mg gosuranemab, with a reduction in neuronal uptake increasing from < 1% to 35% over that range (see Fig. S11).